Solid Biosciences (SLDB) EBIT Margin (2021 - 2022)
Solid Biosciences (SLDB) reported EBIT Margin of 411.44% for Q2 2022, up 10845.0% on a YoY basis from N/an in Q2 2021, and up 68.78% sequentially from 1318.03% in Q1 2022.
Solid Biosciences (SLDB) EBIT Margin (2021 - 2022) Analysis & Trends
Solid Biosciences (SLDB) has 2 years of EBIT Margin data on file, last reported at 411.44% in Q2 2022.
- For the quarter ending Q2 2022, EBIT Margin rose 10845.0% year-over-year to 411.44%; the trailing twelve-month figure through Mar 2023 stood at 1833.52% (down 117226.0% YoY), and the FY2022 full-year result was 1315.2%, down 78470.0% from the prior year.
- EBIT Margin advanced to 411.44% in Q2 2022, from 1318.03% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 411.44% in Q2 2022 to a low of 1318.03% in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Solid Biosciences | 529.40 Mn | 529.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -411.44% |
| Mar 31, 2022 | -1,318.03% |
| Dec 31, 2021 | -591.38% |
| Sep 30, 2021 | -509.78% |
| Jun 30, 2021 | -519.89% |
| Mar 31, 2021 | -506.33% |